Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in cancer therapy
L Shen, B Wang, SP Wang, SK Ji, MJ Fu… - Journal of Medicinal …, 2024 - ACS Publications
Lysine specific demethylase 1 (LSD1), a transcriptional modulator that represses or
activates target gene expression, is overexpressed in many cancer and causes imbalance in …
activates target gene expression, is overexpressed in many cancer and causes imbalance in …
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
M Pelon, P Krzeminski, Z Tracz-Gaszewska… - Frontiers in …, 2024 - frontiersin.org
Multiple myeloma is an incurable cancer that originates from antibody-producing plasma
cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin …
cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin …
Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma
N Puccio, G Manzotti, E Mereu, F Torricelli… - …, 2020 - haematologica.org
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of
clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized by a highly …
clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized by a highly …